Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

Azafaros Appoints Chief Operating Officer and Head of Finance

Beyond Biotech podcast 35: Rare Disease Day

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress

BREAKING NEWS: Azafaros Receives FDA’s IND Clearance and Fast Track Designation

Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposiumâ„¢ Conference

Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis

Azafaros Announces Multiple Presentations at 18th Annual WORLDSymposiumâ„¢

Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorderss

Azafaros expands executive management team and operations

Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline

Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders